Effective acute desensitization for immediate-type hypersensitivity to human granulocyte-monocyte colony stimulating factor

Annals of Allergy, Asthma and Immunology

Volumn 83, Issue 6 I, 1999, Pages 543-546

  Shahar, E ^a   Krivoy, N ^b   Pollack, Simon ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DESENSITIZATION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MUCOCUTANEOUS CANDIDIASIS; NEUTROPENIA; PRICK TEST; PRIORITY JOURNAL; RECURRENT INFECTION;

EID: 0033372538     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62867-0     Document Type: Article

References (17)

1. Clark SC, Kamen R. The human hematopoietic colony stimulating factors. Science 1987;236:1229-1237.
2. Steward WP. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993;342:153-157.
3. Ruef C, Coleman DL. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990;12:41-62.
4. Herrman F, Schultz G, Linderman A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989;7: 159-167.
5. Fleischman RA. Clinical use of hemopoietic growth factors. Am J Med Sci 1993;305:248-273.
6. Stern AC, Jones TC. The side-effect profile of GM-CSF. Infection 1992; 20(Suppl):124-127.
7. Djeu JY. Cytokines and anti-fungal immunity. Adv Exp Med Biol 1992; 319:217-223.
8. Ganser A, Volkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: a phase I/II trial. Blood 1989;73:31-37.
9. Engler RJM, Weiss RB. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony stimulating factor associated with a positive prick skin test reaction. Ann Allergy Asthma Immunol 1996;76: 531-534.
10. Horn TD, Burke PJ, Karp JE, et al. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol 1991;127:49-2.
11. Mehregan DR, Fransway AF, Edmonson JH, et al. Cutaneous reactions to granulocyte-monocyte colony-stimulating factor. Arch Dermatol 1992;128: 1055-1060.
12. Steger GG, Locker G, Rainer H, et al. Cutaneous reactions to GM-CSF in inflammatory breast cancer. N Engl J Med 1992;327:286.
13. Shahar E, Krivoy N, Pollack S. White cell enhancement in the treatment of severe candidosis [letter to the editor]. Lancet 1995;346:974-975.
14. Sullivan TJ. Drug Allergy. In: Midleton E, Jr, ed. Allergy, principles, and practice. 4th ed. St. Louis: CV Mosby Co, 1993:1725-1746.
15. Ohman JL, Jr. Clinical and immunologic responses to immunotherapy. In: Lockey RF, Bukantz SC, eds. Allergen immunotherapy. New York: Marcel Decker, Inc, 1991:209-232.
16. Yunginger JW. Insect allergy. In: Midleton E, Jr, ed. Allergy, principles, and practice. 4th ed. St. Louis: CV Mosby Co, 1993:1511-1514.
17. Patterson R, De Swarte RD, Green-berger PA, et al. Drug allergy and protocols for management of drug allergies. N Engl Reg Allergy Proc 1986; 7:325.